Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios A. Dimopoulos,Sara Bringhen,Pekka Anttila,Marcelo Capra,Michele Cavo,Craig E. Cole,Cristina Gasparetto,Vania Hungria,Matthew W Jenner,Vladimir I. Vorobyev,Eduardo Yanez Ruiz,Jian Y Yin,Rao Saleem,Maeva Hellet,Sandrine Macé,Bruno Paiva,Ravi Vij +16 more
TLDR
Adding dexamethasone to isatuximab increased response rates and survival outcomes with no detrimental effect on safety in relapsed/refractory multiple myeloma.About:
This article is published in Blood.The article was published on 2021-03-04 and is currently open access. It has received 35 citations till now. The article focuses on the topics: Progression-free survival.read more
Citations
More filters
Journal ArticleDOI
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
TL;DR: In this article, clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma patients were evaluated using a clinical efficacy assessment.
Journal ArticleDOI
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
TL;DR: FlowCT as discussed by the authors is a semi-automated workspace empowered to analyze large data sets, including pre-processing, normalization, multiple dimensionality reduction techniques, automated clustering, and predictive modeling tools.
Journal ArticleDOI
Antibody therapies for multiple myeloma
TL;DR: Antibody therapy has significantly enhanced the armamentarium against MM and further research should focus on tailoring the combination regimens based on disease and patient characteristics in order to optimize the efficacy and safety.
Journal ArticleDOI
Boosting Immunity against Multiple Myeloma
Raquel Lopes,Bruna Ferreira,Joana Caetano,Filipa Barahona,Emilie Arnault Carneiro,Cristina João +5 more
TL;DR: A review of current and future strategies used for immunomodulation of multiple myeloma focusing on the impact on the bone marrow immunome is provided in this article, where the authors provide an overview of the most promising strategies to achieve a sustained MRD negativity with prolonged survival.
Journal ArticleDOI
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Xavier Leleu,Thomas Martin,Katja Weisel,Fredrik Schjesvold,Shinsuke Iida,Fabio Malavasi,Salomon Manier,Chang-Ki Min,Enrique M. Ocio,Charlotte Pawlyn,Aurore Perrot,Hang Quach,Joshua Richter,Ivan Spicka,Kwee Yong,Paul G. Richardson +15 more
TL;DR: Isatuximab and daratumumab possess similarities and differences in their mechanisms of action, likely imparted by their binding to distinct, nonoverlapping epitopes on the CD38 molecule as discussed by the authors .
References
More filters
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Journal ArticleDOI
FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype
TL;DR: Differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc Gamma receptor IIIa-158V/F polymorphism at amino-acid position 158.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Philippe Moreau,J F San Miguel,Pieter Sonneveld,Maria-Victoria Mateos,Elena Zamagni,Hervé Avet-Loiseau,Roman Hájek,Meletios A. Dimopoulos,Heinz Ludwig,H. Einsele,Sonja Zweegman,Thierry Facon,Michele Cavo,Evangelos Terpos,H. Goldschmidt,M. Attal,Christian Buske +16 more
TL;DR: These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO) incidence and epidemiology Multiple myeloma accounts for 1% ofall cancers and ∼10% of all haematological malignancies.
Journal ArticleDOI
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W.C.J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser +14 more
TL;DR: Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Related Papers (5)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal,Paul G. Richardson,S. Vincent Rajkumar,Jesús F. San-Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Kathryn P. Corzo,Frank Campana,Solenn Le-Guennec,Franck Dubin,Kenneth C. Anderson,Vincent Rajkumar,Simon J. Harrison,Wojt Janowski,Ian Kerridge,Andrew Spencer,Michel Delforge,Karel Fostier,Philip Vlummens,Ka Lung Wu,Richard Leblanc,Michel Pavic,Michael Sebag,Roman Hájek,Vladimir Maisnar,Ludek Pour,Henrik Gregersen,Lotfi Benbouker,Denis Caillot,Martine Escoffre-Barbe,Thierry Facon,Laurent Frenzel,Cyrille Hulin,Lionel Karlin,Brigitte Kolb,Brigitte Pegourie,Aurore Perrot,Mourad Tiab,Laure Vincent,Dietger Niederwieser,Achilles Anagnostopoulos,Sosana Delimpasi,Marie Christine Kyrtsonis,Anargyros Symeonidis,Árpád Illés,Gabor Mikala,Zsolt Nagy,Sara Bringen,Paolo Corradini,Ciceri Fabio,Roberto M. Lemoli,Anna Marina Liberati,Chiara Nozzoli,Renato Zambello,Shinsuke Iida,Takashi Ikeda,Satoshi Iyama,Morio Matsumoto,Chihiro Shimazaki,Kazutaka Sunami,Kenshi Suzuki,Michihiro Uchiyama,Youngil Koh,Ki-Hyun Kim,Jae Hoon Lee,Chang-Ki Min,Hillary Blacklock,Hugh Goodman,AJ Neylon,David Simpson,Sebastian Grosicki,Artur Jurczyszyn,Adam Walter-Croneck,Krzysztof Warzocha,Luis Araujo,Claudia Moreira,Vadim A Doronin,Larisa P. Mendeleeva,Vladimir I. Vorobyev,Andrej Vranovsky,Adrian Alegre,Mercedes Gironella,Marta Sonia Gonzalez Perez,Carmen Montes,Enrique M. Ocio,Paula Rodriguez,Mats Hardling,Birgitta Lauri,Ming Chung Wang,Su Peng Yeh,Mutlu Arat,Fatih Demirkan,Zafer Gulbas,Sevgi Kalayoglu Besisik,Ihsan Karadogan,Tulin Tuglular,Ali Ünal,Filiz Vural,Jonathan Sive,Matthew Streetly,Kwee Yong,Jason Tache +111 more